What’s the current market cap for Haemonetics stock?

Haemonetics (HAE) has a market cap of $3B as of May 26, 2026.

What is the P/E ratio for Haemonetics stock?

The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 31.95 as of May 26, 2026.

Does Haemonetics stock pay dividends?

No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of May 26, 2026.

When is the next Haemonetics dividend payment date?

Haemonetics (HAE) stock does not pay dividends to its shareholders.

What is the beta indicator for Haemonetics?

Haemonetics (HAE) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Haemonetics stock | $HAE Share Price

13:30

15:10

16:45

18:25

20:00

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Ticker

$HAE

Sector

Health

Primary listing

NYSE

Employees

3,009

Headquarters

Boston, United States

Website

www.haemonetics.com

Haemonetics Metrics

BasicAdvanced

$3bn

31.95

$2.05

0.53

What the Analysts think about Haemonetics

Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.

Bulls say / Bears say

Haemonetics posted adjusted EPS of $1.29 for Q4 FY2026, exceeding estimates by $0.02, with revenue up 4.8% year-over-year to $346.4 million—demonstrating strong execution (Reuters).

The Hospital segment was the standout in Q4, reporting 8.0% growth, and 7% organic growth, underscoring robust demand for hospital transfusion and blood management solutions (Reuters).

Haemonetics’ acquisition of Vivasure Medical on January 9, 2026, for up to €185 million, broadens its hospital product lineup, especially with the PerQseal Elite vascular closure devices, reinforcing its presence in fast-growing therapeutic areas (Reuters).

Adjusted gross margin decreased by 50 basis points to 59.7% in Q4 FY2026, impacted by an unfavorable product mix and tariff pressures, which raises concerns about ongoing profitability (Reuters).

The Blood Center segment grew by only 0.7% in Q4, indicating strong competition and limited opportunities for increasing market share within a mature segment (Reuters).

Management's guidance for FY2027 organic revenue growth of 3% to 6% points to a moderate outlook, potentially trailing behind other medical devices peers (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 12 May 2026.

Haemonetics Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Haemonetics Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HAE

Capital at risk

Market open

Upcoming events

No upcoming events